文献速递肝病

血清FABP1水平升高与对乙酰氨基酚诱导的急性肝衰竭患者生存率较低相关

Elevated FABP1 serum levels are associated with poorer survival in acetaminophen-induced acute liver failure.
PubMed 文献 · Hepatology · 2017-01-19

基于美国急性肝衰竭研究组登记库1998-2014年的198例对乙酰氨基酚诱导急性肝衰竭患者(99例存活者、99例死亡者)的巢式病例对照研究显示,存活者早期和晚期血清FABP1水平均显著低于死亡者,FABP1升高与21天死亡率增加相关,将FABP1加入现有预后模型可显著提高判别能力,但作者指出FABP1作为临床预测工具仍需进一步研究验证。

要点

  • 对乙酰氨基酚诱导急性肝衰竭存活者早期血清FABP1为238.6 ng/mL,显著低于死亡者的690.8 ng/mL(P < 0.0001)。
  • FABP1 > 350 ng/mL与早期(P = 0.0004)和晚期(P < 0.0001)死亡风险显著升高相关。
  • 将FABP1加入King's College标准或急性肝衰竭研究组预后指数可显著改善判别能力(P < 0.002)。

核心结论

  • 在对乙酰氨基酚诱导的急性肝衰竭患者中,FABP1可能具有较好区分存活者与死亡者的潜力,并可能改善目前临床使用的模型;FABP1作为该病的临床预测工具仍需进一步研究验证。

研究设计与样本

  • 巢式病例对照研究,纳入美国急性肝衰竭研究组登记库1998-2014年的198例对乙酰氨基酚诱导急性肝衰竭患者,其中存活者99例、死亡者99例,采用酶联免疫吸附试验检测血清FABP1。

主要发现

  • 存活者早期血清FABP1为238.6 ng/mL,死亡者为690.8 ng/mL(P < 0.0001);存活者晚期血清FABP1为148.4 ng/mL,死亡者为612.3 ng/mL(P < 0.0001)。
  • FABP1 > 350 ng/mL与早期(P = 0.0004)和晚期(P < 0.0001)死亡风险显著升高相关。
  • 校正显著协变量(终末期肝病模型、血管升压药使用)后,早期log FABP1比值比为1.31(P = 0.027),晚期log FABP1比值比为1.50(P = 0.005),均与21天死亡率显著增加相关。
  • 早期和晚期多变量模型的受试者工作特征曲线下面积分别为0.778和0.907。
  • King's College标准的受试者工作特征曲线下面积早期单独为0.552、加入FABP1为0.711,晚期单独为0.604、加入FABP1为0.797;急性肝衰竭研究组预后指数早期单独为0.686、加入FABP1为0.766,晚期单独为0.711、加入FABP1为0.815,加入FABP1后均显著改善(P < 0.002)。

临床怎么用

  • 作者认为FABP1可能具有较好区分对乙酰氨基酚诱导急性肝衰竭存活者与死亡者的潜力,并可能改善目前临床使用的模型;FABP1作为该病的临床预测工具仍需进一步研究验证。

局限性

  • 作者指出FABP1作为对乙酰氨基酚诱导急性肝衰竭的临床预测工具仍需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Acetaminophen (APAP)-induced acute liver failure (ALF) is associated with significant mortality. Traditional prognostic scores lack sensitivity. Serum liver-type fatty acid binding protein (FABP1) early (day 1) or late (day 3-5) levels are associated with 21-day mortality in the absence of liver transplant. Serum samples from 198 APAP-ALF patients (nested case-control study with 99 survivors, 99 nonsurvivors) were analyzed by enzyme-linked immunosorbent assay with clinical data from the US Acute Liver Failure Study Group registry (1998-2014). APAP-ALF survivors had significantly lower serum FABP1 levels early (238.6 versus 690.8 ng/mL, P < 0.0001) and late (148.4 versus 612.3 ng/mL, P < 0.0001) compared with nonsurvivors. FABP1 > 350 ng/mL was associated with significantly higher risk of death at early (P = 0.0004) and late (P < 0.0001) time points. Increased serum FABP1 early (log FABP1 odds ratio = 1.31, P = 0.027) and late (log FABP1 odds ratio = 1.50, P = 0.005) were associated with significantly increased 21-day mortality after adjusting for significant covariates (Model for End-Stage Liver Disease, vasopressor use). Areas under the receiver operating characteristic curve for early and late multivariable models were 0.778 and 0.907, respectively. The area under the receiver operating characteristic curve of the King's College criteria (early, 0.552 alone, 0.711 with FABP1; late, 0.604 alone, 0.797 with FABP1) and the Acute Liver Failure Study Group prognostic index (early, 0.686 alone, 0.766 with FABP1; late, 0.711 alone, 0.815 with FABP1) significantly improved with the addition of FABP1 (P < 0.002 for all). CONCLUSION: In patients with APAP-ALF, FABP1 may have good potential to discriminate survivors from nonsurvivors and may improve models currently used in clinical practice; validation of FABP1 as a clinical prediction tool in APAP-ALF warrants further investigation. (Hepatology 2017;65:938-949).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Karvellas CJ, Speiser JL, Tremblay M, et al. Elevated FABP1 serum levels are associated with poorer survival in acetaminophen-induced acute liver failure. Hepatology. 2017. PMID: 27859489. doi:10.1002/hep.28945

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。